Editor's Choice by Seggie, Janet
EDITOR’S CHOICE
153       March 2014, Vol. 104, No. 3
CME: Spina bifida
This month’s education component (and that of the April issue) 
deals with the problem of spina bifida, which is the most common 
permanently disabling birth defect. In South Africa (SA), it affects an 
estimated 0.77 - 6.1/1 000 live births, with higher incidences in rural 
areas. Genetic and environmental factors act together to cause the 
condition, which ranges in severity from occult spinal dysraphism, 
signalled by a dimple (or red marks, hyperpigmented patches, tufts of 
hair or small lumps) in an infant’s lower back to meningomyelocele 
(complicated by hydrocephalus in ~80 - 90% of cases). The latter 
requires surgery within 2 - 3 days of birth to prevent infection and 
preserve neurological function. We include a review[1] and summaries 
of full articles (available online).
Adopting a beneficial lifestyle for 
cardiovascular protection
Opie and Dalby offer us a review[2] of how we might, and encourage 
our patients to, adopt favourable lifestyles to promote protection 
from cardiovascular disease (CVD). Their focus is on those studies 
with ‘hard’ endpoints, namely cardiovascular events and/or mortality. 
Beneficial lifestyle factors are: non-smoking; exercise for ≥30 min 3 - 5 
times per week at moderate walking pace, which notably, is as good 
as an intensive walking pace; maintaining an ideal body weight on an 
ideal diet; and a modest alcohol intake. The Mediterranean diet – the 
beneficial components being high intake of vegetables, legumes, fruits 
and nuts, cereal, fish, and monounsaturated fats with small amounts of 
meat, poultry, and high-fat dairy products – reduces mortality by 25%, 
coronary heart disease deaths by 33%, and cancer by 24%. 
Markers for CVD risk in HIV
HIV-related CVD is under-recognised and the clinical assessment 
thereof is a critical challenge for practitioners, especially in SA. 
Besides the traditional risk factors for CVD, in people living with 
HIV there are specific factors that potentially increase the risk 
for developing CVD: chronic inflammation; metabolic changes 
associated with the infection; therapy; and lipodystrophy. Van 
Rooyen et al.[3] offer us cardiometabolic markers to identify CVD 
risk in HIV-infected black South Africans. Despite the limitations 
and the relatively small size of this study, these authors propose 
that by employing lipid ratios and high-density lipoprotein 
cholesterol (HDL-C) levels for screening, early identification 
of South Africans living with HIV and at risk for CVD may be 
achieved. A triglyceride (TG):HDL-C ratio ≥1.49, total cholesterol 
(TC):HDL-C ratio ≥5.4 and an HDL-C level ≤0.76  mmol/l was 
indicative of CVD risk.
Rational dosing of colistin
Globally, multidrug-resistant (MDR) Gram-negative bacilli causing 
nosocomial infections (notably in Klebsiella pneumoniae, Pseudomonas 
aeruginosa, Enterobacter spp. and Acinetobacter baumannii) have 
become an important emerging threat. In SA, carbapenem resistance 
is emerging in K.  pneumoniae and Enterobacter spp., while high 
levels of resistance to all antimicrobial classes are observed among 
P.  aeruginosa and A.  baumannii, the latter having emerged as a 
common pathogen in intensive care units. 
There are good theoretical grounds to suggest that colistin should 
be used in combination with other effective antibacterials to treat 
such infections, especially in patients with normal renal function 
and when treating bacteria with minimum inhibitory concentrations 
>1  mg/l. Visser Kift et al.[4] used information gleaned from their 
systematic review to develop simple recommendations for rational 
dosing (refer to Table 1 on pg. 185). It is imperative that colistin is 
dosed appropriately to minimise the risk of resistance as it is a last-
line agent against MDR Gram-negative bacteria and the pipeline of 
new drugs in development for these organisms is limited. Access to 
colistin needs to be made easier in SA, especially in the public sector 
where carbapenem resistance is increasing. 
Improved imaging for diagnosis of 
childhood TB
An Editorial from Belard et al.[5] alerts us to the value of focused 
assessment with sonography for HIV/TB (FASH) in children. FASH 
is a bedside ultrasound that has been developed to improve detection 
of extrapulmonary tuberculosis (EPTB) in HIV-infected adults, 
becoming one of the most applied modules in adult emergency 
rooms in SA. Being well tolerated and non-invasive, it is especially 
promising and, because of the relatively high frequency of EPTB in 
young children, its yield in identifying abdominal nodes, hepatic or 
splenic hypoechoic lesions as well as pericardial, pleural or ascitic 
effusions – all indications of EPTB – is high. Windows for mediastinal 
ultrasound include the suprasternal notch and parasternal intercostal 
spaces, which allow for detection of enlarged lymph nodes in the 
superior and anterior mediastinum.
Research ethics evolution
Since its original formulation, the Declaration of Helsinki (DOH) [6] 
has undergone seven revisions and two clarifications, with the 
most recent revision recently adopted during the World Medical 
Association Assembly by an overwhelming majority (>75%) of 
member associations. Some of the main changes include a more 
readable structure, revised paragraphs on vulnerable groups, Research 
Ethics Committees, post-study provisions and the introduction of 
compensation for research-related injuries and a specific reference 
to biobanks. As it reaches its 50th anniversary in 2014, the DOH 
remains one of the most authoritative statements on ethical standards 
for human research in the world. It is a set of principles that has kept 
up with advances in science and technology. 
SA’s progress towards the MDGs
This month’s supplement reveals SA’s progress towards the 
Millennium Development Goals (MDGs).[7] MDGs 4, 5 and 6 are 
directly related to health and the functioning of the healthcare 
system. MDG 4 relates to reducing child mortality, MDG 5 speaks 
to improving maternal health and MDG 6 to combating HIV/AIDS, 
malaria and other diseases, such as TB. Targets were set for countries 
to reach by 31 December 2015, using the year 1990 as a baseline. 
This supplement has a number of papers that describe the progress 
that SA has made in reaching some of these targets and some of the 
continuing challenges that need to be overcome to meet, or at least 
get as close to reaching, the targets as possible.
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